Overview

NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Status:
RECRUITING
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
Phase:
PHASE3
Details
Lead Sponsor:
Neurocrine Biosciences